Market access update
Market access update
During this session, expert speakers discussed how different healthcare systems are evaluating and financing the introduction of innovative medicines and other new technologies that can improve patient outcomes and support equitable access.
In single-payer systems such as Taiwan, innovative models have been implemented to improve patient care, such as the use of cloud storage for patient medical data, reimbursement framework to validate the real-world benefits of new treatments, and value based payment model enabled through analysis of big data from TW NHI Research Database.
In Singapore, the recent Healthier SG policy has led to more investment in preventive health to support a higher quality of life and control cost inflation.
Private organizations, such as pharmaceutical companies, expressed the desire to be viewed by governments more as “partners” than “vendors”, and encouraged transparent discussions that could give rise to new sustainable financing models to improve patient access to innovative treatments.
Innovative financing models are even more critical in emerging markets where access to basic healthcare for all remains a high priority.
To prevent over-burdening the healthcare system, value-based pricing model can be used to support patient access to new treatments.
The role of insurance companies is critical in filling the healthcare funding gaps that governments are unable to cover due to limited budgets.
Employers are in a position where they could play a more active role to support the financing of treatments for their employees, since the majority of employees would have a corporate insurance scheme.
A full synopsis from the Zuellig Summit is available to download now. This report summarizes the key takeaways from all of the expert sessions:
The Asia-Pacific region is characterized by its dynamic nature and rapidly evolving markets. These are critical to the future growth plans of our pharmaceutical and biotechnology clients, and we are leading many ground-breaking market access projects in the region.
PRMA Consulting, part of Fishawack Health, will help you bring out the best in your asset, using our extensive market access and disease area experience. Get in touch for a confidential conversation about your policy, access, value, and evidence needs.
Building a healthier Asia